Drugs / PEG-IFN alfa-2a
PEG-IFN alfa-2a
also known as
PEG-IFNα-2a · peginterferon alfa-2a · PEG-IFNa · PEG-IFNα · Pegasys · Pegylated interferon alfa-2a · pegylated interferon α-2a
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05729139 | Jul 2023 → Jul 2026 | skin squamous cell carcinoma | Baptist Health South Florida | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02637999 | Feb 2014 → Jan 2016 | hepatitis D virus infection | Hepatera Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02888106 | Apr 2016 → Nov 2019 | chronic hepatitis B virus infection | Hepatera Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03719313 | Dec 2018 → Oct 2022 | hepatitis D virus infection | Eiger BioPharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01753557 | Dec 2012 → Nov 2014 | chronic hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT02594293 | Oct 2015 → Sep 2022 | chronic hepatitis B virus infection | Huashan Hospital | Completed | Met primary |
| Phase 4 | NCT00192647 | Aug 2004 → Mar 2009 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | Missed primary |
| Comparator or background therapy7 trials | ||||||
| Phase 2 | NCT01332955 Background | Apr 2011 → Sep 2013 | HIV infectious disease, chronic hepatitis C virus infection | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00980330 Background | Oct 2009 → Aug 2011 | hepatitis C virus infection | Tibotec Pharmaceuticals, Ireland | Completed | Met primary |
| Phase 2 | NCT00932971 Comparator | Jun 2009 → Aug 2017 | hepatitis D virus infection | HepNet Study House, German Liverfoundation | Completed | No outcome recorded |
| Phase 2 | NCT00561015 Background | Dec 2007 → Jun 2008 | chronic hepatitis C virus infection | Tibotec BVBA | Completed | No outcome recorded |
| Phase 2 | NCT00528528 Background | Oct 2007 → Jul 2009 | chronic hepatitis C virus infection | Tibotec BVBA | Completed | No outcome recorded |
| Phase 3 | NCT00703118 Background | Oct 2008 → Jul 2010 | chronic hepatitis C virus infection | Tibotec BVBA | Completed | Met primary |
| Phase 4 | NCT02644538 Comparator | Dec 2015 → Dec 2017 | chronic hepatitis B virus infection | The Second Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-11-20 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis and Roche Enter Exclusive Pegasys Partnership in China for Viral Hepatitis ascletis.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peg-IFN alfa2a | “One discontinue the NUC treatment ,receive Peg-IFN alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks” NCT02594293 ↗15“Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.” NCT00528528 ↗ “Biological: pegIFN alfa-2a” NCT01332955 ↗ |
| Known as | PEG-IFNa | “Treatment with PEG-IFNa with or without tenofovir disoproxil fumarate (TDF) for 96 weeks resulted in HDV RNA suppression” PMID 37787009 ↗ Oct 2023 |
| Known as | PEG-IFNα | “Until recently, pegylated interferon-alfa-2a (PEG-IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV).” PMID 41317314 ↗ Nov 2025 |
| Known as | PEG-IFNα-2a | “AIM: To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and...” PMID 27062488 ↗ Jun 20161“The effect of pegylated interferon alpha-2a (PegIFN-α-2a) on virological relapse after NUC cessation is unknown.” PMID 39094743 ↗ Jul 2024 |
| Known as | Pegasys | “Peg-IFN alfa2a (Pegasys)” NCT00528528 ↗ |
| Known as | peginterferon alfa-2a | “HBeAg-negative patients received peginterferon alfa-2a (180 μg/week) ± lamivudine (100 mg/day) for 48 weeks as part of a multicenter, randomized study.” PMID 23518903 ↗ Mar 20121“peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.” PMID 30833068 ↗ Mar 2019 |
| Known as | Pegylated interferon alfa-2a | “Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally” NCT00932971 ↗ |
| Known as | pegylated interferon α-2a | “AIM: To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and...” PMID 27062488 ↗ Jun 2016 |
| Modality | Protein / enzyme biologic | “pegylated interferon (Peg-IFN)-alfa-2a solution for subcutaneous injection” NCT00528528 ↗ |
| Route | Subcutaneous | “360 micrograms (mcg) subcutaneous (SC) once weekly” NCT00192647 ↗ |